Publications by authors named "Thomas O Kleen"

Since the publication of the Society for Immunotherapy of Cancer's (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular therapies, and tumor vaccines to unleash antitumor immune activity. The most notable feature of these breakthroughs is the achievement of durable clinical responses in some patients, enabling long-term survival. These durable responses have been noted in tumor types that were not previously considered immunotherapy-sensitive, suggesting that all patients with cancer may have the potential to benefit from immunotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Recent advances in cancer immunotherapies are improving treatment outcomes for various types of cancer by leveraging the immune system to better control tumors.
  • Despite these therapies' successes, not all patients benefit, and some face significant side effects, highlighting the need for better predictive and prognostic biomarkers.
  • The Society for Immunotherapy of Cancer (SITC) formed a task force to explore new technologies and strategies for biomarker discovery, focusing on immune checkpoint blockade therapy and addressing challenges in current research.
View Article and Find Full Text PDF

A novel form of immune cell quantification in blood and tissue is described using epigenetic - based, quantitative real-time PCR assisted cell counting (qPACC). The methylation status of the chromatin structure of either actively expressed or silenced genes is the basis of the epigenetic-based cell identification and quantification technology. Discovery of cell type specific removal of methyl groups (demethylation) from the 5'-carbon of the cytosine base in the dinucleotide cytosine phosphate guanine permits precise and robust quantification of immune cells from only small amounts of human blood or tissue samples.

View Article and Find Full Text PDF

Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting.

View Article and Find Full Text PDF
Article Synopsis
  • The International Society for the Biological Therapy of Cancer (iSBTc) is working with the FDA to improve how scientists study cancer and the immune system.
  • They want to find better ways to measure immune responses in clinical trials and discover new markers that can help understand how cancer affects the body.
  • Two groups are set up to create best practices, and they will share their findings at a special workshop during a big meeting in Washington DC in Fall 2009.
View Article and Find Full Text PDF

CD8(+) T cells play a crucial role in the control of viral infections such as HIV. The functional characterization of HIV-specific CD8(+) T cells has so far been largely restricted to studies of IFN-gamma. The TCR-triggered release of the effector molecules perforin (PFN) and granzyme B (GzB), however, is thought to be a central pathway for the destruction of virus-infected target cells by CD8(+) effector T cells.

View Article and Find Full Text PDF

Background: Lower incidence and severity of acute graft versus host disease (GVHD) has been observed in leukemia patients receiving HLA-mismatched umbilical cord (UCB) transplants. However, despite the increased use of UCB in stem cell transplantation, the mechanisms underlying these favorable outcomes are not well delineated.

Methods: We analyzed antigen specific lymphocyte responses after transplant to determine whether the decreased allogeneic responsiveness of UCB lymphocytes is attributable to pan-unresponsiveness, lymphocyte repressive or recipient-specific tolerance.

View Article and Find Full Text PDF

Objective: To examine antigen specific cytotoxic effector T cell diversity in HIV infected individuals.

Design: We used a panel of previously defined HLA class I-restricted HIV peptides to stimulate CD8 cells in freshly isolated peripheral blood mononuclear cells of HIV infected patients, to determine cognate killing via the perforin-granzyme pathway and inflammation induced by secretion of interferon (IFN)-gamma.

Methods: ELISPOT assays were used to measure the secretion of granzyme B (GzB) and IFN-gamma at single cell resolution.

View Article and Find Full Text PDF